Minimal Residual Disease Testing Market Size & Growth Forecast 2027–2036, By Segments (Technology, Cancer Type, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Minimal Residual Disease Testing Market size was valued at USD 3 billion in 2026 and is projected to grow at a 12.54% CAGR from 2027 to 2036, attaining USD 9.78 billion by 2036. The industry revenue for 2027 is estimated at USD 3.32 billion.
Get more details on this report
Request Free Sample ReportMinimal Residual Disease Testing Market Intelligence Snapshot
Regional Market Dynamics
- North America captured 48.92% of the market in 2026 through advanced oncology diagnostics, widespread molecular testing adoption, and strong integration of disease monitoring into treatment decisions.
- Asia Pacific is projected to grow at a 12.66% CAGR, supported by expanding precision oncology, stronger laboratory capacity, and wider adoption of molecular testing in routine cancer care.
Segment Momentum
- Flow Cytometry captured a 43.53% share in 2026 because its established laboratory workflows support efficient sample processing and routine residual disease monitoring in hematology practice.
- Hematological Malignancy is the fastest-growing cancer type segment, with a 66.52% share in 2026, driven by the ongoing need for frequent residual disease monitoring to guide treatment and detect relapse.
Market Expansion Drivers
- Rising global cancer incidence and hematological malignancies driving demand for sensitive MRD monitoring.
- Advancements in NGS, digital PCR, and flow cytometry improving MRD testing accuracy and automation.
- Expanding reimbursement coverage and clinical guideline integration accelerating routine adoption of MRD testing.
Leading Market Participants
- Major players in the minimal residual disease testing market include Adaptive Biotechnologies Corporation (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (United States), Exact Sciences Corporation (United States), Natera, Inc. (United States), Guardant Health, Inc. (United States), Foundation Medicine, Inc. (United States), QIAGEN N.V. (Netherlands), GRAIL, LLC (United States), Veracyte, Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 3 billion
- 2027 Estimated Market Size: USD 3.32 billion.
- Projected Market Size: USD 9.78 billion by 2036
- Growth Forecast: 12.54% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Flow Cytometry (Technology) | Hematological Malignancy (Cancer Type) | Hospitals and Specialty Clinics (End Use)
- Emerging Opportunity Segment: Polymerase Chain Reaction (PCR) (Technology) | Hematological Malignancy (Cancer Type) | Diagnostic Laboratories (End Use)
Market Growth Drivers and Industry Trends
Rising global cancer incidence and hematological malignancies driving demand for sensitive MRD monitoring
Rising cancer incidence and the growing prevalence of hematological malignancies are supporting minimal residual disease testing market growth by increasing the need for sensitive monitoring of residual disease. Greater emphasis on detecting remaining disease activity creates demand for testing approaches capable of supporting more precise patient monitoring during clinical management.
Advancements in NGS, digital PCR, and flow cytometry improving MRD testing accuracy and automation
Technological progress in NGS, digital PCR, and flow cytometry is helping propel minimal residual disease testing market growth by enhancing testing accuracy and automation. Improvements across these methods strengthen the ability to detect residual disease with greater sensitivity while making testing workflows more efficient and supporting broader laboratory implementation.
Expanding reimbursement coverage and clinical guideline integration accelerating routine adoption of MRD testing
Expanding reimbursement coverage and greater integration of MRD testing into clinical guidelines will boost minimal residual disease testing market demand by making testing more accessible within routine care pathways. Reimbursement support can facilitate broader utilization, while guideline integration reinforces the role of MRD monitoring in established clinical workflows.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Adoption of minimal residual disease testing in oncology | 3.80% | Short term (≤ 2 yrs) | North America, Europe | Medium | Fast |
| Expansion of clinical and diagnostic laboratory services | 3.70% | Medium term (2–5 yrs) | Europe, Asia Pacific | Medium | Moderate |
| Innovation in highly sensitive testing technologies | 3.80% | Long term (5+ yrs) | North America, Asia Pacific | Medium | Moderate |
| Rising global cancer incidence and hematological malignancies driving demand for sensitive MRD monitoring | 2.80% | Moderate | North America, Europe | High | Near Term |
| Advancements in NGS, digital PCR, and flow cytometry improving MRD testing accuracy and automation | 3.00% | High | North America, Asia Pacific | High | Near Term |
| Expanding reimbursement coverage and clinical guideline integration accelerating routine adoption of MRD testing | 2.20% | High | North America, Europe, Asia Pacific | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
The minimal residual disease testing market was led by North America in 2026, with a 48.92% share, reflecting advanced oncology infrastructure, strong adoption of precision medicine, and widespread availability of sophisticated molecular and cellular diagnostic technologies. Minimal residual disease assessment is increasingly important for evaluating treatment response, detecting persistent malignant cells, and supporting disease monitoring in hematologic cancers. The region's established clinical laboratories and specialized cancer centers provide a strong foundation for the adoption of sensitive diagnostic methods, including flow cytometry and molecular testing approaches. Growing emphasis on personalized treatment strategies is also increasing the clinical value of highly sensitive disease-monitoring technologies. Continued advances in genomic analysis, laboratory automation, and biomarker detection are improving testing capabilities and supporting more precise clinical decision-making. Strong research activity in hematologic oncology further encourages integration of MRD assessment into treatment pathways, while established healthcare infrastructure facilitates access to advanced diagnostic services.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is experiencing the fastest growth in the minimal residual disease testing market as oncology care infrastructure expands and precision diagnostics become more widely adopted. Increasing investment in specialized cancer centers and clinical laboratories is improving access to advanced testing technologies, while growing awareness of personalized treatment is encouraging clinicians to use more sensitive methods for monitoring therapeutic response. The expansion of molecular diagnostics and flow cytometry capabilities is strengthening regional capacity for detecting low levels of residual disease. Rising healthcare investment and the modernization of laboratory infrastructure are also supporting broader availability of sophisticated oncology testing. At the same time, pharmaceutical and clinical research activity is increasing demand for reliable disease-monitoring tools that can support treatment development and patient management. These developments are improving diagnostic capabilities across the region and creating favorable conditions for accelerated adoption of minimal residual disease testing.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Standardized Diagnostic IntegrationGermany is prioritizing harmonized testing protocols and laboratory standardization to improve the clinical utility of minimal residual disease assessments. German cancer centers are increasingly incorporating molecular monitoring into treatment evaluation and long-term disease management programs.
France 🇫🇷
Clinical Pathway AlignmentFrance is strengthening the incorporation of minimal residual disease testing into multidisciplinary cancer care and research initiatives. French healthcare institutions are emphasizing evidence generation and diagnostic consistency to support broader use of molecular response monitoring in oncology practice.
Italy 🇮🇹
Specialized Oncology AdoptionItaly is concentrating on expanding access to minimal residual disease testing through specialized oncology and hematology centers. Collaborative research programs in Italy are supporting greater use of molecular diagnostics for treatment assessment and relapse monitoring in blood cancers.
Japan 🇯🇵
Hematology Care EnhancementJapan is focusing on minimal residual disease testing in leukemia management, supported by its advanced molecular diagnostics infrastructure. Healthcare providers in Japan are placing greater attention on sensitive monitoring tools that help refine treatment intensity and recurrence surveillance.
South Korea 🇰🇷
Genomic Testing ExpansionSouth Korea is accelerating the adoption of advanced sequencing platforms and digital diagnostics for minimal residual disease applications. Academic hospitals in South Korea are expanding precision oncology programs that rely on highly sensitive disease monitoring to support individualized treatment strategies.
United States 🇺🇸
Precision Monitoring EcosystemThe U.S. market emphasizes integration of minimal residual disease testing into oncology care pathways and clinical decision-making. Biopharmaceutical collaborations and expanded use of next-generation sequencing are encouraging broader adoption of personalized monitoring strategies across hematologic malignancies in the United States.
Segment Leadership and Growth Trends
Minimal Residual Disease Testing Market Share (%), by Technology, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportTechnology Segment Analysis: Flow Cytometry (Largest Segment) vs Polymerase Chain Reaction (PCR) (Fastest-Growing Segment)
Flow cytometry held the largest position in the minimal residual disease testing market, representing a 43.53% share in 2026, supported by its established use for identifying abnormal cell populations and assessing disease burden in hematological conditions. The technology enables multiparametric analysis of cells, allowing laboratories to distinguish malignant populations based on distinct cellular characteristics. Its established clinical utility, compatibility with routine laboratory workflows, and importance in monitoring treatment response continue to support strong adoption of flow cytometry for MRD assessment.
Polymerase chain reaction (PCR) is projected to witness the fastest growth as demand increases for highly sensitive molecular approaches capable of detecting residual disease at very low levels. PCR-based methods can identify specific genetic or molecular markers associated with malignant cells, enabling more targeted disease monitoring in appropriate clinical settings. Growing emphasis on precise treatment assessment, molecular disease characterization, and personalized cancer management is strengthening interest in PCR-based MRD testing.
Cancer Type Segment Analysis: Hematological Malignancy (Largest & Fastest-Growing Segment)
Hematological malignancy represented the largest and fastest-growing cancer type segment in the minimal residual disease testing market, accounting for a 66.52% share in 2026. MRD assessment has particular importance in blood cancers because residual malignant cells can persist after treatment even when conventional evaluations indicate remission. Sensitive monitoring technologies enable clinicians and researchers to evaluate treatment response, identify persistent disease, and support more informed disease-management strategies. Increasing emphasis on risk stratification, treatment monitoring, and personalized approaches to hematological cancer care continues to reinforce the segment's strong position and growth potential.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Technology | Flow Cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Others | Flow Cytometry | Polymerase Chain Reaction (PCR) |
| Cancer Type | Hematological Malignancy, Leukemia, Lymphoma, Solid Tumors | Hematological Malignancy | Hematological Malignancy |
| End Use | Hospitals and Specialty Clinics, Diagnostic Laboratories, Academic and Research Institutes, Others | Hospitals and Specialty Clinics | Diagnostic Laboratories |
Competitive Landscape and Market Positioning
Prominent players in the minimal residual disease testing market:
1. Adaptive Biotechnologies Corporation (United States)
2. F. Hoffmann-La Roche Ltd. (Switzerland)
3. Thermo Fisher Scientific Inc. (United States)
4. Exact Sciences Corporation (United States)
5. Natera Inc. (United States)
6. Guardant Health Inc. (United States)
7. Foundation Medicine Inc. (United States)
8. QIAGEN N.V. (Netherlands)
9. GRAIL LLC (United States)
10. Veracyte Inc. (United States)
Precision oncology advancements are strengthening clinical relevance in the minimal residual disease testing market. In the minimal residual disease testing market, high-sensitivity molecular detection and sequencing innovations are improving early relapse identification.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Adaptive Biotechnologies Corporation (United States) | |||||||
| F. Hoffmann-La Roche Ltd. (Switzerland) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Exact Sciences Corporation (United States) | |||||||
| Natera Inc. (United States) | |||||||
| Guardant Health Inc. (United States) | |||||||
| Foundation Medicine Inc. (United States) | |||||||
| QIAGEN N.V. (Netherlands) | |||||||
| GRAIL LLC (United States) | |||||||
| Veracyte Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Countable Labs | May-26 | Countable Labs secured $26 million in financing to accelerate the development and global commercialization of its single-molecule PCR technology. This capital infusion supports the scaling of its next-generation molecular diagnostic capabilities, specifically targeting clinical product development and enhancing the company’s competitive positioning in precision cancer monitoring and minimal residual disease testing applications. |
| Personalis | May-26 | Personalis achieved expanded CMS reimbursement coverage for its NeXT Personal MRD test dedicated to cancer immunotherapy monitoring. This milestone significantly lowers barriers to clinical adoption, facilitating broader integration into standard oncology workflows and enhancing the market utility and accessibility of personalized diagnostics for monitoring residual disease progression in real-world healthcare settings. |
| Lucence | Mar-26 | Lucence, in partnership with DXD Hub and NCCS, initiated the $6 million UNITED 2.0 program to develop next-generation cancer profiling technologies. This research initiative focuses on advancing molecular diagnostics with direct implications for precision cancer detection, strengthening collaborative innovation and the long-term potential for integrating these advancements into clinical minimal residual disease testing workflows. |
| NeoGenomics | Jan-25 | NeoGenomics entered a multi-year exclusive strategic commercial partnership with Adaptive Biotechnologies to scale MRD monitoring solutions for patients with specific blood cancers. This collaboration aligns two key market participants to enhance the commercial reach and clinical application of MRD testing, directly impacting competitive dynamics and the adoption of advanced molecular monitoring in hematologic oncology. |
| Foresight Diagnostics | Jan-25 | Foresight Diagnostics secured the inclusion of its ctDNA-MRD testing technology in the National Comprehensive Cancer Network (NCCN) Guidelines for diffuse large B-cell lymphoma. As the first instance of ctDNA-MRD inclusion in these authoritative clinical guidelines, this development establishes a new standard of care, significantly influencing clinical adoption pathways and market demand for validated minimal residual disease diagnostic solutions. |
| QIAGEN | Sep-24 | QIAGEN launched a high-precision digital PCR system designed for clinical oncology, facilitating advanced DNA and RNA quantification for liquid biopsy and cancer monitoring workflows. By enhancing diagnostic accuracy for disease progression tracking, this technology integration supports the broader adoption of molecular testing infrastructure and improves the technical scalability of minimal residual disease detection platforms. |
| Allogene Therapeutics | Jan-24 | Allogene Therapeutics and Foresight Diagnostics formed a strategic alliance to develop an in vitro diagnostic (IVD) for MRD assessment. This partnership aims to standardize monitoring for patient eligibility in the ALPHA3 large B-cell lymphoma study, demonstrating a targeted approach to integrating proprietary diagnostic technology into clinical trial frameworks to validate market-ready MRD solutions. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Minimal Residual Disease Testing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Testing Purpose | Diagnosis and Risk Stratification, Treatment Response Monitoring, Relapse Detection and Surveillance, Treatment Decision-Making |
| Biomarker Type | DNA-Based Biomarkers, RNA-Based Biomarkers, Protein-Based Biomarkers, Cellular Biomarkers |
| Disease Stage | Newly Diagnosed Disease, Post-Treatment Remission, Maintenance Therapy, Suspected or Confirmed Relapse |
Minimal Residual Disease Testing Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Precision Oncology Adoption Assessment |
|
| Clinical Workflow Integration Study |
|
| Personalized Cancer Care Transformation Analysis |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market size of minimal residual disease testing?
How is the minimal residual disease testing industry projected to perform over the next decade?
How are advancements in molecular diagnostic technologies changing the adoption of MRD testing in clinical workflows?
Why is MRD testing becoming more routinely embedded in hematological malignancy management strategies?
Why is Flow Cytometry the leading technology in the minimal residual disease testing market?
Which cancer type is growing fastest in the minimal residual disease testing market?
Why is North America the leading market for minimal residual disease testing?
What is fueling rapid growth in the Asia Pacific minimal residual disease testing market?
Which organizations are considered leaders in the minimal residual disease testing landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization